EDIT Stock Analysis: Buy, Sell, or Hold?
EDIT - Editas Medicine, Inc. Common Stock
$2.01
0.02 (1.01%)
▲
5d:
-2.43%
30d:
-1.95%
90d:
-33.22%
BUY
HIGH Confidence
Last Updated: February 2, 2026
Earnings: Mar 04, 2026
28d
Get Alerted When EDIT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EDIT shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: EDIT shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: EDIT is currently trading at $2.01, which is considered oversold relative to its 30-day fair value range of $2.02 to $2.18.
Technical Outlook: Technically, EDIT is in a strong downtrend. Immediate support is located at $1.92, while resistance sits at $2.43.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.43 (+170.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EDIT is in a strong downtrend. Immediate support is located at $1.92, while resistance sits at $2.43.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.43 (+170.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.02 -
$2.18
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 170.1% below Wall St target ($5.43)
Fair Price Analysis
30-Day Fair Range
$2.02 -
$2.18
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.92
Resistance Level
$2.43
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.77
Wall Street Target
$5.43
(+170.1%)
Revenue Growth (YoY)
12265.6%
Last updated: February 03, 2026 6:50 AM ET
Data refreshes hourly during market hours. Next update: 7:50 AM
Data refreshes hourly during market hours. Next update: 7:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDIT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 54 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 56 HOLD |
